Loading
An experimental PET scan that shows whether a tumour carries the TROP2 protein, so doctors could pick the right ADC before giving it.
89Zr-labelled anti-TROP2 antibodies and 68Ga/18F-labelled TROP2 nanobodies and peptides (Fudan University, Peking Union, others) have been imaged in first-in-human studies in breast, lung, and pancreatic cancer. The goal is non-invasive, whole-body, heterogeneity-aware selection and monitoring for sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan, where IHC has been an unreliable predictor.
A radiolabelled TROP2 binder is imaged; antibody tracers image at 3-6 days with 89Zr, nanobodies within 1-2 hours with 68Ga/18F.
Query for this technology: (TITLE:"TROP2 PET" OR ABSTRACT:"TROP2 PET" OR TITLE:"TROP2 imaging" OR ABSTRACT:"TROP2 imaging" OR TITLE:"Trop-2 PET" OR ABSTRACT:"Trop-2 PET"). Results are unfiltered search hits about TROP2 PET, not a curated reading list.
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Metastatic triple-negative breast cancer and the tag frontier.
Shares Alpha radioligands after ADC failure, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, TROP2, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Immuno-PET and the tag frontier.
Shares PET (positron emission tomography) and the tag frontier.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/